LSE:AZNPharmaceuticals
AstraZeneca Regulatory Wins And Metabolic Push Highlight Valuation Gap
AstraZeneca (LSE:AZN) has received U.S. FDA Priority Review for DATROWAY in advanced triple negative breast cancer.
Imfinzi combined with chemotherapy has been recommended for EU approval in early-stage gastric and gastroesophageal cancers.
The company has expanded its global obesity and diabetes portfolio through a new partnership with CSPC Pharmaceuticals.
AstraZeneca, listed in London as LSE:AZN, is pushing further into oncology while widening its reach in metabolic disease. The Priority...